Last reviewed · How we verify

NCT04791332

A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants

Completed Phase 1 Last updated 28 April 2025
What this trial tests

Phase 1 trial testing JNJ-67953964 in Healthy in 30 participants. Completed in 28 July 2021.

Timeline
30 April 2021
Primary endpoint
28 July 2021
28 July 2021

Quick facts

Lead sponsorJanssen Pharmaceutical K.K.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeother
Enrollment30
Start date30 April 2021
Primary completion28 July 2021
Estimated completion28 July 2021
Sites1 location across Japan

Drugs / interventions tested

Conditions studied

Sponsor

Janssen Pharmaceutical K.K. — full company profile →

Who can join

Adults 20 to 55, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) after single- and multiple-dose oral administration of JNJ-67953964 in healthy Japanese adult male participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of JNJ-67953964

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Janssen Pharmaceutical K.K. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04791332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing